Clinical Trials Arena lists five of the top tweets on oncology in Q2 2022 based on data from GlobalData’s Pharmaceuticals Influencer Platform.
The top tweets are based on total engagements (likes and retweets) received on tweets from more than 181 oncology experts tracked by GlobalData’s Pharmaceuticals Influencer platform during the second quarter (Q2) of 2022.
The most popular tweets on oncology in Q2 2022: Top five
1. Eric Topol’s tweet on machine learning model outperforming oncologists in predicting mortality in patients with advanced cancer
Eric Topol, a physician and scientist, shared a study on oncologists’ performance against a in predicting three-month mortality for patients suffering with metastatic solid tumours in an outpatient setting. The study compared estimates made by medical oncologists and their advanced practice clinicians at the City of Hope academic center and limited community sites, and by a custom model running silently for about 20 months.
Results of the study found a total of 74 oncologists answered 3099 3MSQs for 2,041 patients with advanced cancer. The positive predictive value (PPV) of oncologists was 34.8% and that of the model was 60.0, in this cohort with a 15% prevalence of three-month mortality and 30% sensitivity for both oncologists and the model, the research highlighted.
Username: Eric Topol
Twitter handle: @EricTopol
2. Dr. Anirban Maitra’s tweet on the magnitude of genetic differences between primary and metastatic tumours
Dr. Anirban Maitra, pancreatic cancer researcher and gastrointestinal pathologist, shared a study on understanding the genetic features across 22 cancer types with high representation from patients with primary and metastatic tumours. The analyses revealed that metastatic tumours shared common genomic qualities, such as high genomic instability, stronger enrichment of structural variants (SVs), and low intra-tumor heterogeneity, but fewer short mutations than primary tumours. However, the scale of genomic differences between primary and metastatic tumors was found to be highly cancer type specific and strongly influenced by exposure to cancer treatments. In all, prostate, breast, thyroid, breast, and pancreas neuroendocrine cancers showed an intense transformation of the genomic landscape in advanced tumorigenic stages.
The study further revealed that the genomic differences in kidney, thyroid, and pancreas neuroendocrine carcinomas could not be associated to genomic markers of therapy resistance, which might indicate alternative evolutionary dynamics independent of cancer therapy. Another nine cancer types, including cervix, colorectal, and others, showed moderate genomic differences, while the genomic landscape of the eight remaining cancers, including sarcoma, ovarian cancer, glioblastoma, and others was found to be highly consistent between the primary and metastatic stages, and the minimal differences were attributed to exposure to cancer treatments.
Username: Anirban Maitra
Twitter handle: @Aiims1742
3. Mark A. Lewis’ tweet on the efficacy of neoantigen T-cell receptor (TCR) therapy in pancreatic cancer
Mark A. Lewis, an oncologist, shared a research on TCR therapy targeting mutant KRAS G12D in metastatic pancreatic cancer with durable response. The clinical problem is that pancreatic ductal adenocarcinoma is unaffected by immunotherapy, possibly because this cancer lacks neoantigen-reactive tumour-infiltrating lymphocytes, the report highlighted. The study investigated a 71-year-old woman suffering from progressing metastatic pancreatic adenocarcinoma who received a single infusion of 16.2×109 autologous T cells. The T cells were genetically modified to clonally produce two allogenic HLA-C*08:02-restricted T-cell receptors (TCRs) that target mutant KRAS G12D expressed by the tumours.
The patient was administered a single dose of intravenous tocilizumab five days prior the infusion to prevent cytokine release syndrome, and intravenous cyclophosphamide on days five and four prior to the infusion, the research detailed. Eight hours after receiving the infusion, the patient started receiving intravenous high-dose interleukin-2 to support the growth of the infused cells. After a month of follow-up, computed tomography showed a regression of the metastatic lung lesions, with an overall objective partial response of 62%. After six months, tumour regression continued with an overall partial response of 72%. Engineered cells represented over 2% of all the circulating T cells at six months, the report detailed.
Username: Mark Lewis
Twitter handle: @marklewismd
4. Jean-Charles Soria’s tweet on engineered cellular immunotherapies in cancer
Jean-Charles Soria, an oncologist and scientist, shared a review on cancer cellular immunotherapy having completed ten years, with chimeric antigen receptor (CAR)-modified T cells for refractory leukaemia. The article detailed that the commercial approval of genetically engineered T cells for treating numerous blood cancers provide hope to patients suffering from other types of cancer.
Additionally, the merging of human genome engineering and cell therapy technology is paving the way for a new class of cellular therapeutics, the article noted. The review, as a result, discussed the objectives of cellular immunotherapy in cancer, its key challenges, and strategies that are being developed to overcome these hurdles. The article further highlighted that advances in the field of cancer are leading the way for cellular immunotherapeutics in other diseases.
Twitter handle: @jsoriamd
5. Dr. Stephen V. Liu’s tweet on the negative impact of acetaminophen (APAP) on cancer immunotherapy
Dr. Stephen V. Liu, an associate professor of medicine at the Georgetown University, shared a report on the impact of APAP on the efficacy of immunotherapy in cancer patients. The research highlighted that APAP use has been linked to blunted vaccine immune responses. However, despite the need for more research to understand the impact of APAP on immunity, exposure to APAP was evaluated by plasma analysis and was linked with clinical outcomes in three independent groups of patients suffering with advanced cancer and who were treated with immune checkpoint inhibitors (ICB).
Immunomodulatory effects of APAP were thereby assessed on a pre-clinical tumour model and on human peripheral blood mononuclear cells (PBMCs) from healthy donors, the report noted. The findings revealed that detectable plasma APAP levels at the time of treatment onset was associated with a suggestively worse clinical outcome in ICB-treated cancer patients, independent of other predictive factors. As a result, the results found that APAP significantly lowered ICB efficacy in the pre-clinical MC38 model, and the production of PD1 blockade-related interferon-γ secretion by human PBMCs. Moreover, reduction of ICB efficacy in vivo was linked with significantly increased tumour infiltration by regulatory T cells (Tregs).
Username: Stephen V Liu
Twitter handle: @StephenVLiu